Related references
Note: Only part of the references are listed.A Physiologically Based Pharmacokinetic Model for Capreomycin
B. Reisfeld et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Simultaneous in vivo RP-HPLC-DAD quantification of multiple-component and drug-drug interaction by pharmacokinetics, using 6,7-dimethylesculetin, geniposide and rhein as examples
Aihua Zhang et al.
BIOMEDICAL CHROMATOGRAPHY (2012)
Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data Comparative Evaluation of Prediction Approaches in Early Pharmaceutical Discovery
An Van den Bergh et al.
CLINICAL PHARMACOKINETICS (2011)
Development and application of a physiologically based pharmacokinetic model for triadimefon and its metabolite triadimenol in rats and humans
Susan Ritger Crowell et al.
TOXICOLOGY LETTERS (2011)
Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway
J-M Zheng et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects
Juan Jose Perez-Ruixo et al.
CLINICAL PHARMACOKINETICS (2008)
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones et al.
CLINICAL PHARMACOKINETICS (2006)
Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes
K Ito et al.
PHARMACEUTICAL RESEARCH (2004)
Prediction of pharmacokinetics prior to in vivo studies.: II.: Generic physiologically based pharmacokinetic models of drug disposition
P Poulin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Share Paper
